Tonix CEO: 'Investors Seeing Value in Reformulation Strategy' - Presented by: The Aol. On Network

Shares of Tonix Pharmaceuticals are up over 35 percent in 2014 because investors are finally starting to appreciate the company's story, says Tonix CEO Dr. Seth Lederman. The biotech, which raised $43 million in a January secondary, is working on prescription medicines for post traumatic stress syndrome, headaches and fibromyalgia.



Related Videos

Most Popular Videos

Latest Videos


Most Active by Volume

Company Last Sale Change Net / %
NOK $ 8.40 0.47 ▲ 5.93%
AAPL $ 104.9235 1.93 ▲ 1.88%
BAC $ 16.681 0.28 ▲ 1.71%
T $ 33.555 0.95 ▼ 2.74%
PBR $ 12.235 0.60 ▼ 4.64%
QQQ $ 98 1.63 ▲ 1.69%
FB $ 80.30 1.93 ▲ 2.46%
YELP $ 59.0668 11.16 ▼ 15.90%

As of 10/23/2014, 12:32 PM
More Most Active